Opendata, web and dolomites

CHARME

Growing bone fast and cost-effective

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CHARME project word cloud

Explore the words cloud of the CHARME project. It provides you a very rough idea of what is the project "CHARME" about.

patient    commercialisation    maturity    cells    clinically    attracting    markets    trl    biotechnology    quality    charme    technological    true    autograft    extra    manufacture    spinal    epitaxos    bv    property    infrastructure    regeneration    put    limited    material    situ    golden    operative    channel    data    materials    xpand    superior    strategy    abundant    successful    2017    induces    allograft    unlike    synthetic    200    generates    nano    bone    commercial    launch    life    inducing    dental    acceptance    million    quantity    approval    stimulate    generation    form    epitaxo    position    submission    body    cell    structure    exceptional    market    processed    regulatory    standard    stem    procedure    patients    marketing    endpoints    tissue    orthopaedic    disadvantages    quantities    seduces    innovative    replace    autologous    adverse    surface    faster    billion    site    trl6    plan    superiority    establishment    graft    technologies    pain    defect    patented   

Project "CHARME" data sheet

The following table provides information about the project.

Coordinator
KUROS BIOSCIENCES BV 

Organization address
address: PROFESSOR BRONKHORSTLAAN 10 G 48
city: BILTHOVEN
postcode: 3723 MB
website: www.xpand-biotech.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.charme-horizon.nl
 Total cost 2˙630˙845 €
 EC max contribution 1˙841˙591 € (70%)
 Programme 1. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
2. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KUROS BIOSCIENCES BV NL (BILTHOVEN) coordinator 1˙841˙591.00

Map

 Project objective

XPAND Biotechnology BV has developed a new generation of orthopaedic materials: the EpitaxOs bone regeneration material.

EpitaxOs (TRL 6) is unique: a) it seduces the body to form bone b) is as effective as the golden standard autograft without its disadvantages (extra operative procedure, pain, limited quantity available) c) it is superior to other synthetic bone graft materials, allograft, growth factors and cell-based technologies d) it is available in abundant quantities e) it increases the quality of life for patients as the use of EpitaxOs has no adverse effects on the patient. The innovative property of EpitaxOs is its patented surface nano-structure, which induces the formation of bone by attracting the patient’s own stem cells to the defect site and stimulate them to make autologous bone (in situ bone tissue regeneration). Similar to autograft and growth factors and unlike other synthetic materials, EpitaxOs is a true bone inducing material, but generates bone much faster

EpitaxOs is targeted at the €4 billion spinal market and the €200 million dental market. The exceptional bone inducing properties of EpitaxOs put it in a unique position to replace autograft, (processed) allograft and growth factors.

The CHARME project aims at bringing EpitaxOs from technological maturity level TRL6 to a successful commercial/ production launch at level TRL 8/9 (in 2017). The objectives are: 1. Development of a commercial scale production infrastructure 2. Regulatory submission of EpitaxOs in key markets 3. Providing evidence-based data to demonstrate product superiority and facilitate product launch & market acceptance 4. Establishment of a marketing channel and development of a strategy for commercialisation of EpitaxOs

The endpoints of the CHARME project will be EpitaxO, a commercial scale infrastructure, to manufacture EpitaxOs, regulatory submission, approval in Europe, clinically relevant study data, a marketing channel, plan for the commercialisation

 Deliverables

List of deliverables.
Distribution targeted information letters to dedicated groups Other 2019-07-25 13:42:30
Scientific articles Documents, reports 2019-07-25 13:42:30
Brochures for patients, surgeons, hospitals Other 2019-07-25 13:42:30
Establish an interactive CHARME webpage. Other 2019-07-25 13:42:30

Take a look to the deliverables list in detail:  detailed list of CHARME deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CHARME" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CHARME" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.1.;H2020-EU.2.1.2.)

S3D (2015)

Feasibility study to determine the use of ITS technology to replace nuclear density meters in mining, dredging and other areas of hydraulic transport.

Read More  

InLineNano (2015)

In-Line Areal Surface Measurement for Micro and Nano Production

Read More  

NANOHIGH (2015)

High volume production facility for high accuracy nanocapsules

Read More